CGP 39551

Key Product Details

Product Description

CGP 39551 is a potent, selective and competitive NMDA antagonist (K_i = 310 nM for inhibition of [³H]-CPP binding in rat brain). Centrally active upon oral administration in vivo.

Product Specifications for CGP 39551

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CGP 39551

The following data is based on the product molecular weight 237.19.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

6 5 4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.22 mL	21.08 mL	42.16 mL
5 mM	0.84 mL	4.22 mL	8.43 mL
10 mM	0.42 mL	2.11 mL	4.22 mL
50 mM	0.08 mL	0.42 mL	0.84 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 14 publications citing the usage of this product.

• Fagg CGP 37849 and CGP 39551: novel and potent competitive N-MthD.-asparate receptor antagonists with oral activity. Br.J.Pharmacol. 1990 PMID: 1972895
• Loscher and Honack Anticonvulsant and behavioural effects of two novel competitive N-MthD.-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamaz. J.Pharmacol.Exp.Ther. 1991 PMID: 1671593
• D'Hooge Effects of competitive NMDA receptor antagonists on excitatory amino-acid-evoked currents in mouse spinal cord. Fundam.Clin.Pharmacol. 1999 PMID: 10027090

Product Documents for CGP 39551